{
  "id": 285,
  "text": "It is recently approved by US FDA for triage of patients positive for highrisk HPV.Potential biomarkers currently under research include TOP2A, MCM2, HPV viral load, viral E4 protein, viral DNA methylation, host DNA methylation, 3q chromosomal gain, microRNAs, etc (44).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: It is recently approved by US FDA for triage of patients positive for highrisk HPV.Potential biomarkers currently under research include TOP2A, MCM2, HPV viral load, viral E4 protein, viral DNA methylation, host DNA methylation, 3q chromosomal gain, microRNAs, etc (44).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "针对高危HPV阳性患者的分类处理，目前已被批准或正在研究的生物标志物包括以下几类：\n\n1. **已批准的生物标志物**：  \n   例如 p16/Ki-67 双染检测已获得 FDA 批准，可用于辅助高危 HPV 阳性患者的分流管理。\n\n2. **正在研究的潜在生物标志物**：  \n   - **DNA 复制/增生标志物**：如 TOP2A 和 MCM2，反映细胞增殖活动。  \n   - **HPV 病毒的特异标志物**：如病毒载量（HPV viral load）、病毒 E4 蛋白表达（viral E4 protein）。  \n   - **DNA 甲基化标志物**：包括病毒 DNA 甲基化（HPV viral DNA methylation）和宿主 DNA 甲基化（host DNA methylation），有助于鉴别潜在癌前病变。  \n   - **染色体异常**：如 3q 染色体增益（3q chromosomal gain）已显示与宫颈癌前病变和癌症风险相关。  \n   - **microRNAs**：即小分子非编码 RNA，与肿瘤调控相关，具有潜在诊断价值。\n\n以上生物标志物的研究和临床应用，有助于优化高危 HPV 阳性患者的分流和早期干预策略。",
  "query": "针对高危HPV阳性患者的分类处理，目前有哪些已经被批准或正在研究的生物标志物？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 针对高危HPV阳性患者的分类处理，目前有哪些已经被批准或正在研究的生物标志物？\n\n<reference text>: It is recently approved by US FDA for triage of patients positive for highrisk HPV.Potential biomarkers currently under research include TOP2A, MCM2, HPV viral load, viral E4 protein, viral DNA methylation, host DNA methylation, 3q chromosomal gain, microRNAs, etc (44).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "针对高危HPV阳性患者的分类处理，目前已被批准或正在研究的生物标志物包括以下几类：\n\n1. **已批准的生物标志物**：  \n   例如 p16/Ki-67 双染检测已获得 FDA 批准，可用于辅助高危 HPV 阳性患者的分流管理。\n\n2. **正在研究的潜在生物标志物**：  \n   - **DNA 复制/增生标志物**：如 TOP2A 和 MCM2，反映细胞增殖活动。  \n   - **HPV 病毒的特异标志物**：如病毒载量（HPV viral load）、病毒 E4 蛋白表达（viral E4 protein）。  \n   - **DNA 甲基化标志物**：包括病毒 DNA 甲基化（HPV viral DNA methylation）和宿主 DNA 甲基化（host DNA methylation），有助于鉴别潜在癌前病变。  \n   - **染色体异常**：如 3q 染色体增益（3q chromosomal gain）已显示与宫颈癌前病变和癌症风险相关。  \n   - **microRNAs**：即小分子非编码 RNA，与肿瘤调控相关，具有潜在诊断价值。\n\n以上生物标志物的研究和临床应用，有助于优化高危 HPV 阳性患者的分流和早期干预策略。"
}